NCT07600996 · RECRUITING
A Prospective Observational Study of Cerebrospinal Fluid Mitochondrial Biomarkers Measured by Flow Cytometry in Patients With Ischemic Stroke and Alzheimer Disease Controls
This observational study is collecting leftover spinal fluid from patients already having a lumbar puncture for clinical reasons — either for ischemic stroke or Alzheimer disease — and analyzing it with a lab technique called flow cytometry to measure markers of mitochondrial health. The goal is to see whether these markers differ between the two conditions and whether they correlate with stroke severity and recovery. This is not a treatment trial; it is early-stage biological discovery work.
Eligibility criteria
Inclusion Criteria: * Age 18 years or older. Patients treated at Xuanwu Hospital, Capital Medical University between March 2026 and May 2026. Diagnosis of ischemic stroke or Alzheimer disease according to standard clinical diagnostic criteria. Diagnostic lumbar puncture performed for clinical indications as part of routine medical care. Availability of residual cerebrospinal fluid after completion of clinically required testing. Ability to provide written informed consent, or availability of a legally authorized representative to provide consent when appropriate. For ischemic stroke patients, availability of baseline neurological assessment and planned follow-up for 90-day modified Rankin Scale assessment. Exclusion Criteria: * Lumbar puncture performed solely for research purposes rather than clinical indication. Insufficient residual cerebrospinal fluid volume for research flow cytometry analysis. Grossly bloody or severely contaminated cerebrospinal fluid sample that precludes reliable flow cytometry analysis. Known central nervous system infection, malignant meningitis, or other inflammatory or neoplastic condition that, in the investigator's judgment, may substantially confound cerebrospinal fluid mitochondrial measurements. Inability to obtain informed consent from the participant or legally authorized representative. Missing key clinical outcome data, including admission NIHSS, discharge NIHSS, or planned 90-day mRS follow-up for ischemic stroke participants. Any condition judged by the investigator to make the participant unsuitable for inclusion in the study.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-05-22